In vitro testing to a panel of potential chemotherapeutics and current concepts of chemotherapy in benign meningiomas

Balik, Vladimír; Šulla, I; Park, Hun Ho; Šarišský, Marek

doi:10.1016/j.suronc.2015.06.004

Cited by 7 publications

(3 citation statements)

References 53 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Problematic with the various hydroxyurea trials, however, is that many patients had not failed to respond to radiotherapy or that radiotherapy was administered concurrently. Although there was the largest retrospective study of hydroxyurea in recurrent WHO grade I meningioma patients, all previously treated with surgery and radiotherapy and in whom no further surgery or radiotherapy was applicable, there were no radiographic responses and 35% of patients had SD [ 13 20 21 22 23 ]. There are several major differences in the present study compared with previous studies; 1) the tumors were confined to WHO grade II meningioma, not included WHO grade I or III meningiomas, 2) the tumors were resected incompletely, 3) hydroxyurea chemotherapy started after surgery as soon as possible without long break, and 4) the patients who underwent hydroxyurea chemotherapy were all radiotherapy-naïve.…”

Section: Discussionmentioning

confidence: 99%

The Clinical Outcome of Hydroxyurea Chemotherapy after Incomplete Resection of Atypical Meningiomas

Kim

2017

Brain Tumor Res Treat

View full text Add to dashboard Cite

BackgroundThe aim of this study is to investigate the clinical results of adjuvant chemotherapy with hydroxyurea and to compare those with the results of postoperative radiotherapy after incomplete resection of atypical meningiomas (ATMNGs).MethodsWe retrospectively reviewed the medical records of 84 patients with ATMNGs diagnosed in the period from January 2000 to December 2014. Clinical data included patient sex and age at the time of surgery, presenting symptoms at diagnosis, location and size of tumor, extent of surgery, use of postoperative radiotherapy or hydroxyurea chemotherapy, duration of follow-up, and progression. In terms of the extent of surgical resection, incomplete resection was defined as Simpson grade II–V.ResultsAmong the 85 patients, 55 (65.5%) patients underwent incomplete resection; 24 (43.6%) were treated with adjuvant hydroxyurea (group A), and 20 (36.4%) with postoperative radiotherapy (group B), and 11 (20.0%) underwent conservative treatment after surgery (group C). Twenty-five (45.5%) patients experienced the progression of tumors during the follow-up period (mean 47.7 months, range 12.4-132.1 months); 8 of 24 (33.3%) patients in group A, 7 of 20 (35.0%) patients in group B, and 10 of 11 (90.9%) patients in group C. The mean progression-free survival (PFS) was 30.9 months (range 6.4-62.3 months); 46.2 months in group A, 40.4 months in group B, and 11.9 months in group C (p=0.041). Multivariate analysis showed that Simpson grade (p=0.040), adjuvant treatment after surgery (p<0.001), increased Ki67 (p=0.017), mitotic index (p=0.034), and overexpression of p53 (p=0.026) predicted longer PFS.ConclusionThis investigation suggested that adjuvant treatment after incomplete resection of ATMNGs are associated with longer PFS than conservative treatment, and that there is no difference of PFS between hydroxyurea chemotherapy and radiotherapy after surgery. Therefore, hydroxyurea chemotherapy can be considered as another adjuvant tool for the ATMNGs if the postoperative adjuvant radiotherapy cannot be applicable.

show abstract

Section: Discussionmentioning

confidence: 99%

The Clinical Outcome of Hydroxyurea Chemotherapy after Incomplete Resection of Atypical Meningiomas

Kim

2017

Brain Tumor Res Treat

View full text Add to dashboard Cite

show abstract

“…In another study, an in vitro review of animal and human studies revealed the potential of chemotherapy as a second or third-line treatment for benign meningiomas. That study demonstrated the importance of considering histopathologically benign variants, as this characteristic may be significant in tumor responsiveness to specific chemotherapeutic agents ( 85 ).…”

Section: Systemic Therapy In Meningiomasmentioning

confidence: 87%

Intracranial meningiomas: an update of the 2021 World Health Organization classifications and review of management with a focus on radiation therapy

Yarabarla,

Mylarapu,

Han

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Meningiomas account for approximately one third of all primary intracranial tumors. Arising from the cells of the arachnoid mater, these neoplasms are found along meningeal surfaces within the calvarium and spinal canal. Many are discovered incidentally, and most are idiopathic, although risk factors associated with meningioma development include age, sex, prior radiation exposure, and familial genetic diseases. The World Health Organization grading system is based on histologic criteria, and are as follows: grade 1 meningiomas, a benign subtype; grade 2 meningiomas, which are of intermediately aggressive behavior and usually manifest histologic atypia; and grade 3, which demonstrate aggressive malignant behavior. Management is heavily dependent on tumor location, grade, and symptomatology. While many imaging-defined low grade appearing meningiomas are suitable for observation with serial imaging, others require aggressive management with surgery and adjuvant radiotherapy. For patients needing intervention, surgery is the optimal definitive approach with adjuvant radiation therapy guided by extent of resection, tumor grade, and location in addition to patient specific factors such as life expectancy. For grade 1 lesions, radiation can also be used as a monotherapy in the form of stereotactic radiosurgery or standard fractionated radiation therapy depending on tumor size, anatomic location, and proximity to dose-limiting organs at risk. Optimal management is paramount because of the generally long life-expectancy of patients with meningioma and the morbidity that can arise from tumor growth and recurrence as well as therapy itself.

show abstract

“…The use of chemotherapy as an additional treatment for patients with recurrent meningioma was considered by Balik et al. The authors showed that in vitro chemosensitivity was most effectively obtained with cisplatin ( 76 ), which was shown to inhibit cell proliferation via upregulation of miR-16 in neuroblastoma both in vivo and in vitro ( 77 ). Additionally, therapeutic applications of miRs represent a novel strategy to influence clinical outcomes in cancer patients.…”

Section: Discussionmentioning

confidence: 99%

MicroRNAs miR-16 and miR-519 control meningioma cell proliferation via overlapping transcriptomic programs shared with the RNA-binding protein HuR

et al. 2023

View full text Add to dashboard Cite

IntroductionMeningiomas are the most common type of primary central nervous system tumors. In about 80% cases, these tumors are benign and grow very slowly, but the remainder 20% can unlock higher proliferation rates and become malignant. In this study we examined two miRs, miR-16 and miR-519, and evaluated their role in tumorigenesis and cell growth in human meningioma.MethodsA cohort of 60 intracranial grade 1 and grade 2 human meningioma plus 20 healthy meningeal tissues was used to quantify miR-16 and miR-519 expressions. Cell growth and dose-response assays were performed in two human meningioma cell lines, Ben-Men-1 (benign) and IOMM-Lee (aggressive). Transcriptomes of IOMM-lee cells were measured after both miR-mimics transfection, followed by integrative bioinformatics to expand on available data. ResultsIn tumoral tissues, we detected decreased levels of miR-16 and miR-519 when compared with arachnoid cells of healthy patients (miR-16: P=8.7e-04; miR-519: P=3.5e-07). When individually overexpressing these miRs in Ben-Men-1 and IOMM-Lee, we observed that each showed reduced growth (P<0.001). In IOMM-Lee cell transcriptomes, downregulated genes, among which ELAVL1/HuR (miR-16: P=6.1e-06; miR-519:P=9.38e-03), were linked to biological processes such as mitotic cell cycle regulation, pre-replicative complex, and brain development (FDR<1e-05). Additionally, we uncovered a specific transcriptomic signature of miR-16/miR-519-dysregulated genes which was highly enriched in HuR targets (>6-fold; 79.6% of target genes). DiscussionThese results were confirmed on several public transcriptomic and microRNA datasets of human meningiomas, hinting that the putative tumor suppressor effect of these miRs is mediated, at least in part, via HuR direct or indirect inhibition.

show abstract

In vitro testing to a panel of potential chemotherapeutics and current concepts of chemotherapy in benign meningiomas

Cited by 7 publications

References 53 publications

The Clinical Outcome of Hydroxyurea Chemotherapy after Incomplete Resection of Atypical Meningiomas

The Clinical Outcome of Hydroxyurea Chemotherapy after Incomplete Resection of Atypical Meningiomas

Intracranial meningiomas: an update of the 2021 World Health Organization classifications and review of management with a focus on radiation therapy

MicroRNAs miR-16 and miR-519 control meningioma cell proliferation via overlapping transcriptomic programs shared with the RNA-binding protein HuR

Contact Info

Product

Resources

About